Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejim.2020.05.021 http://scihub22266oqcxt.onion/10.1016/j.ejim.2020.05.021 32482597!7242960!32482597     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Intern+Med 2020 ; 76 (ä): 43-49 Nephropedia Template TP {{tp|p=32482597|t=2020. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study |pdf=|usr=}}{{32482597}} gab.com Text Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study JO: Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32482597 #FOAvip BACKGROUND: Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy. METHODS: We performed a retrospective study on severe COVID-19 patients with hyper-inflammatory features admitted outside intensive care units (ICUs). Patients treated with intravenous TCZ in addition to standard of care were compared to patients treated with standard of care alone. Safety and efficacy were assessed over a 28-day follow-up. RESULTS: 65 patients were included. Among them, 32 were treated with TCZ. At baseline, all patients were on high-flow supplemental oxygen and most (78% of TCZ patients and 61% of standard treatment patients) were on non-invasive ventilation. During the 28-day follow-up, 69% of TCZ patients experienced a clinical improvement compared to 61% of standard treatment patients (p = 0.61). Mortality was 15% in the tocilizumab group and 33% in standard treatment group (p = 0.15). In TCZ group, at multivariate analysis, older age was a predictor of death, whereas higher baseline PaO2:FiO2 was a predictor of clinical improvement at day 28. The rate of infection and pulmonary thrombosis was similar between the two groups. CONCLUSIONS: At day 28, clinical improvement and mortality were not statistically different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials. Twit Text FOAVip Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study ????Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32482597 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32482597 #FOAvip English Wikipedia <ref>{{Cite pmid|32482597}}</ref> Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study #MMPMID32482597 Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L Eur J Intern Med 2020[Jun]; 76 (ä): 43-49 PMID32482597show ga BACKGROUND: Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy. METHODS: We performed a retrospective study on severe COVID-19 patients with hyper-inflammatory features admitted outside intensive care units (ICUs). Patients treated with intravenous TCZ in addition to standard of care were compared to patients treated with standard of care alone. Safety and efficacy were assessed over a 28-day follow-up. RESULTS: 65 patients were included. Among them, 32 were treated with TCZ. At baseline, all patients were on high-flow supplemental oxygen and most (78% of TCZ patients and 61% of standard treatment patients) were on non-invasive ventilation. During the 28-day follow-up, 69% of TCZ patients experienced a clinical improvement compared to 61% of standard treatment patients (p = 0.61). Mortality was 15% in the tocilizumab group and 33% in standard treatment group (p = 0.15). In TCZ group, at multivariate analysis, older age was a predictor of death, whereas higher baseline PaO2:FiO2 was a predictor of clinical improvement at day 28. The rate of infection and pulmonary thrombosis was similar between the two groups. CONCLUSIONS: At day 28, clinical improvement and mortality were not statistically different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials. |*Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects[MESH] |*Coronavirus Infections/blood/mortality/physiopathology/therapy[MESH] |*Oxygen Inhalation Therapy/methods[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/blood/diagnosis/drug therapy/etiology/mortality/physiopathology/therapy[MESH] |*Respiratory Insufficiency/etiology/therapy[MESH] |Aged[MESH] |Antiviral Agents/adverse effects[MESH] |Betacoronavirus/drug effects/isolation & purification[MESH] |COVID-19[MESH] |Female[MESH] |Humans[MESH] |Italy/epidemiology[MESH] |Male[MESH] |Middle Aged[MESH] |Outcome and Process Assessment, Health Care[MESH] |Receptors, Interleukin-6/*antagonists & inhibitors[MESH] |Retrospective Studies[MESH]Efficacy and safety of tocilizumab in severe COVID-19 patients: a sing(epmc).pdf DeepDyve Pubget Overpricing